Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023 16:01 ET
|
Invivyd
Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels testedPlans to pursue rapid initiation of...
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
July 27, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
July 17, 2023 07:00 ET
|
Invivyd
Continued favorable safety and tolerability profile for all dose levels testedSerum samples from all dose levels tested showed robust neutralization activity against Omicron XBB.1.5, one of the...
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
June 26, 2023 07:00 ET
|
Invivyd
Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype...
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
June 22, 2023 07:00 ET
|
Invivyd
VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to date As predicted by pre-clinical in vitro testing, early serum samples from the first,...
Invivyd to Participate at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023 16:01 ET
|
Invivyd
Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data...
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
May 04, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
April 25, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...